Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a well-established and effective class of T2DM drugs that mimic the effect of native GLP-1 by enhancing glucose-dependent insulin secretion, suppressing glucagon release, and reducing hepatic glucose production [7,8]. Here, GLP1R is linked to type 2 diabetes mellitus.